Concern about that link, particularly relating to teenage boys and young men, has been a key argument against administering ...

We use the TipRanks Stock Comparison tool to see how Wall Street analysts are rating Novavax, BioNTech, and Moderna, and ...

Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become ...

Vaccine experts said the memo was irresponsible and omits key details about how officials arrived at the conclusion.

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Moderna recently faced pressure after the U.S. Food and Drug Administration announced plans to require more rigorous safety ...

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 ...

Piper Sandler 37th Annual Healthcare Conference December 2, 2025 11:00 AM ESTCompany ParticipantsJames Mock - Chief ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.